Magenta Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MGTA and buy or sell other stocks, ETFs, and their options commission-free!About MGTA
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.
CEOMarino Garcia, MBA
CEOMarino Garcia, MBA
Employees78
Employees78
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2015
Founded2015
Employees78
Employees78
MGTA Key Statistics
Market cap513.83M
Market cap513.83M
Price-Earnings ratio-11.86
Price-Earnings ratio-11.86
Dividend yield—
Dividend yield—
Average volume543.13K
Average volume543.13K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$45.46
52 Week high$45.46
52 Week low$13.37
52 Week low$13.37
Stock Snapshot
Magenta Therapeutics(MGTA) stock is priced at $11.99, giving the company a market capitalization of 513.83M. It carries a P/E multiple of -11.86.
Magenta Therapeutics(MGTA) stock opened on 2025-12-17 at —. The price climbed to — and dipped to —.
Magenta Therapeutics(MGTA) shares are trading with a volume of 0, against a daily average of 543.13K.
In the last year, Magenta Therapeutics(MGTA) shares hit a 52-week high of $45.46 and a 52-week low of $13.37.
In the last year, Magenta Therapeutics(MGTA) shares hit a 52-week high of $45.46 and a 52-week low of $13.37.
People also own
Based on the portfolios of people who own MGTA. This list is generated using Robinhood data, and it’s not a recommendation.